Barclays Issues Positive Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its target price lifted by Barclays from $55.00 to $58.00 in a research note published on Thursday morning,Benzinga reports. Barclays currently has an equal weight rating on the stock.

Several other research firms have also weighed in on LIVN. Robert W. Baird increased their target price on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. Wolfe Research upgraded shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a report on Tuesday, May 20th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a report on Tuesday, May 13th. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $59.71.

LivaNova Price Performance

Shares of LIVN stock opened at $52.86 on Thursday. The stock has a 50-day moving average price of $46.22 and a 200 day moving average price of $43.02. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -13.59 and a beta of 0.92. LivaNova has a 12 month low of $32.48 and a 12 month high of $57.35.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. During the same quarter in the prior year, the firm posted $0.93 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. Research analysts expect that LivaNova will post 2.85 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LIVN. Envestnet Asset Management Inc. boosted its position in LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company’s stock valued at $2,034,000 after purchasing an additional 5,850 shares during the last quarter. Russell Investments Group Ltd. boosted its position in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares during the last quarter. Invesco Ltd. boosted its position in LivaNova by 0.6% during the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company’s stock valued at $5,158,000 after purchasing an additional 667 shares during the last quarter. Sterling Capital Management LLC raised its stake in LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after buying an additional 1,441 shares during the period. Finally, Mariner LLC raised its stake in LivaNova by 8.4% in the fourth quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after buying an additional 446 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.